Drug Profile
Clesrovimab - Merck Sharp & Dohme
Alternative Names: Anti RSV F antibody - Merck Sharp & Dohme; MK-1654Latest Information Update: 06 Oct 2022
Price :
$50
*
At a glance
- Originator Merck Sharp & Dohme
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Respiratory syncytial virus infections
Most Recent Events
- 14 Sep 2022 Merck Sharp & Dohme completes a phase I/II trial in Respiratory tract infections (In infants; In neonates; Prevention) in USA, Chile, Colombia, South Korea, South Africa, Spain (IM) (NCT03524118) (EudraCT2017-005062-21)
- 17 Feb 2022 Merck completes a phase I trial in Healthy volunteers in USA
- 31 Dec 2021 Merck & Co has patent protection for clesrovimab in USA, before December 2021